Artemis Medicare Services Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 3, 2025, 8:37 pm

Competitors of Artemis Medicare Services Ltd

All Competitor Stocks of Artemis Medicare Services Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:35 pm

Below is a detailed analysis of the quarterly data for Artemis Medicare Services Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 250.00 Cr.. The value appears strong and on an upward trend. It has increased from 235.00 Cr. (Mar 2025) to 250.00 Cr., marking an increase of 15.00 Cr..
• For Expenses, as of Jun 2025, the value is 209.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 199.00 Cr. (Mar 2025) to 209.00 Cr., marking an increase of 10.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 5.00 Cr..
• For OPM %, as of Jun 2025, the value is 16.00%. The value appears strong and on an upward trend. It has increased from 15.00% (Mar 2025) to 16.00%, marking an increase of 1.00%.
• For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 5.00 Cr..
• For Interest, as of Jun 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 30.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Mar 2025) to 30.00 Cr., marking an increase of 1.00 Cr..
• For Tax %, as of Jun 2025, the value is 29.00%. The value appears to be increasing, which may not be favorable. It has increased from 20.00% (Mar 2025) to 29.00%, marking an increase of 9.00%.
• For Net Profit, as of Jun 2025, the value is 21.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2025) to 21.00 Cr., marking a decrease of 2.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.54. The value appears to be declining and may need further review. It has decreased from 1.69 (Mar 2025) to 1.54, marking a decrease of 0.15.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:24 pm

Growth

Last Updated: September 4, 2025, 11:40 pm

Balance Sheet

Last Updated: December 4, 2025, 12:58 am

Below is a detailed analysis of the balance sheet data for Artemis Medicare Services Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
• For Reserves, as of Sep 2025, the value is 873.00 Cr.. The value appears strong and on an upward trend. It has increased from 828.00 Cr. (Mar 2025) to 873.00 Cr., marking an increase of 45.00 Cr..
• For Borrowings, as of Sep 2025, the value is 274.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 280.00 Cr. (Mar 2025) to 274.00 Cr., marking a decrease of 6.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 255.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 221.00 Cr. (Mar 2025) to 255.00 Cr., marking an increase of 34.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 1,416.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,343.00 Cr. (Mar 2025) to 1,416.00 Cr., marking an increase of 73.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 780.00 Cr.. The value appears strong and on an upward trend. It has increased from 729.00 Cr. (Mar 2025) to 780.00 Cr., marking an increase of 51.00 Cr..
• For CWIP, as of Sep 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 3.00 Cr..
• For Investments, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
• For Other Assets, as of Sep 2025, the value is 584.00 Cr.. The value appears strong and on an upward trend. It has increased from 559.00 Cr. (Mar 2025) to 584.00 Cr., marking an increase of 25.00 Cr..
• For Total Assets, as of Sep 2025, the value is 1,416.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,343.00 Cr. (Mar 2025) to 1,416.00 Cr., marking an increase of 73.00 Cr..

Notably, the Reserves (873.00 Cr.) exceed the Borrowings (274.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Artemis Medicare Services Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 3.62 (Mar 24) to 5.37, marking an increase of 1.75.
• For Diluted EPS (Rs.), as of Mar 25, the value is 5.31. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 5.31, marking an increase of 1.78.
• For Cash EPS (Rs.), as of Mar 25, the value is 9.25. This value is within the healthy range. It has increased from 6.58 (Mar 24) to 9.25, marking an increase of 2.67.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 55.90. It has increased from 28.46 (Mar 24) to 55.90, marking an increase of 27.44.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.88. It has increased from 33.47 (Mar 24) to 60.88, marking an increase of 27.41.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 68.09. It has increased from 64.67 (Mar 24) to 68.09, marking an increase of 3.42.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 13.43. This value is within the healthy range. It has increased from 10.31 (Mar 24) to 13.43, marking an increase of 3.12.
• For PBIT / Share (Rs.), as of Mar 25, the value is 10.15. This value is within the healthy range. It has increased from 7.34 (Mar 24) to 10.15, marking an increase of 2.81.
• For PBT / Share (Rs.), as of Mar 25, the value is 7.82. This value is within the healthy range. It has increased from 5.04 (Mar 24) to 7.82, marking an increase of 2.78.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 5.97. This value is within the healthy range. It has increased from 3.62 (Mar 24) to 5.97, marking an increase of 2.35.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.00. This value is within the healthy range. It has increased from 3.62 (Mar 24) to 6.00, marking an increase of 2.38.
• For PBDIT Margin (%), as of Mar 25, the value is 19.72. This value is within the healthy range. It has increased from 15.94 (Mar 24) to 19.72, marking an increase of 3.78.
• For PBIT Margin (%), as of Mar 25, the value is 14.90. This value is within the healthy range. It has increased from 11.35 (Mar 24) to 14.90, marking an increase of 3.55.
• For PBT Margin (%), as of Mar 25, the value is 11.49. This value is within the healthy range. It has increased from 7.79 (Mar 24) to 11.49, marking an increase of 3.70.
• For Net Profit Margin (%), as of Mar 25, the value is 8.77. This value is within the healthy range. It has increased from 5.59 (Mar 24) to 8.77, marking an increase of 3.18.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.81. This value is within the healthy range. It has increased from 5.59 (Mar 24) to 8.81, marking an increase of 3.22.
• For Return on Networth / Equity (%), as of Mar 25, the value is 10.74. This value is below the healthy minimum of 15. It has decreased from 12.91 (Mar 24) to 10.74, marking a decrease of 2.17.
• For Return on Capital Employeed (%), as of Mar 25, the value is 12.23. This value is within the healthy range. It has decreased from 12.67 (Mar 24) to 12.23, marking a decrease of 0.44.
• For Return On Assets (%), as of Mar 25, the value is 6.08. This value is within the healthy range. It has increased from 5.05 (Mar 24) to 6.08, marking an increase of 1.03.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.27. This value is within the healthy range. It has decreased from 0.59 (Mar 24) to 0.27, marking a decrease of 0.32.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.31. This value is within the healthy range. It has decreased from 0.66 (Mar 24) to 0.31, marking a decrease of 0.35.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.80. It has decreased from 0.93 (Mar 24) to 0.80, marking a decrease of 0.13.
• For Current Ratio (X), as of Mar 25, the value is 2.49. This value is within the healthy range. It has increased from 0.97 (Mar 24) to 2.49, marking an increase of 1.52.
• For Quick Ratio (X), as of Mar 25, the value is 2.45. This value exceeds the healthy maximum of 2. It has increased from 0.92 (Mar 24) to 2.45, marking an increase of 1.53.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 93.21. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 93.21, marking an increase of 93.21.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.45. This value is below the healthy minimum of 20. It has decreased from 12.44 (Mar 24) to 7.45, marking a decrease of 4.99.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.82. This value is below the healthy minimum of 20. It has decreased from 6.83 (Mar 24) to 4.82, marking a decrease of 2.01.
• For Earning Retention Ratio (%), as of Mar 25, the value is 92.55. This value exceeds the healthy maximum of 70. It has increased from 87.56 (Mar 24) to 92.55, marking an increase of 4.99.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.18. This value exceeds the healthy maximum of 70. It has increased from 93.17 (Mar 24) to 95.18, marking an increase of 2.01.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 5.78. This value is within the healthy range. It has increased from 4.48 (Mar 24) to 5.78, marking an increase of 1.30.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.57. This value is within the healthy range. It has increased from 2.57 (Mar 24) to 3.57, marking an increase of 1.00.
• For Enterprise Value (Cr.), as of Mar 25, the value is 3,636.78. It has increased from 2,505.47 (Mar 24) to 3,636.78, marking an increase of 1,131.31.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has increased from 2.85 (Mar 24) to 3.88, marking an increase of 1.03.
• For EV / EBITDA (X), as of Mar 25, the value is 19.68. This value exceeds the healthy maximum of 15. It has increased from 17.89 (Mar 24) to 19.68, marking an increase of 1.79.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has increased from 2.63 (Mar 24) to 4.04, marking an increase of 1.41.
• For Retention Ratios (%), as of Mar 25, the value is 92.54. This value exceeds the healthy maximum of 70. It has increased from 87.55 (Mar 24) to 92.54, marking an increase of 4.99.
• For Price / BV (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has decreased from 6.06 (Mar 24) to 4.92, marking a decrease of 1.14.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has increased from 2.63 (Mar 24) to 4.04, marking an increase of 1.41.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness